IDH1 and low-grade astrocytoma: We created an astrocytoma patient survival prediction model consisting of CHI3L1 and OPN expression levels and patient IDH1 mutational status, which predicted two-year astrocytoma patient survival with accuracy rates of 86.8% in all astrocytomas and 93.8% in low-grade astrocytomas (LGG).